Trovagene between clinical collaboration with Dana-Farber Cancer Institute -
Trovagene, Inc. (NASDAQ: Trov) today announced it has entered into a clinical collaboration with Dana-Farber Cancer Institute to study the usefulness of quantitative detection of urine based change and the ability to monitor the burden of mutation of the tumor and treatment response over time in patients with melanoma metastatic.
under the agreement, urine samples will be taken in patients with locally advanced or metastatic melanoma known to harbor oncogenic mutations driver. An oncology team Dana-Farber, led by Jason Luke, M.D., conduct clinical studies to monitor the oncogenic mutations in DNA-based study of subjects without urinary cell analytical sample. Studies will be designed to collect data on the clinical status of patients, the treatment effect, and long-term results of treatment using noninvasive molecular diagnostic technology Trovagene.
"Although significant advances precision cancer treatments made, the current monitoring technologies are either invasive or do not provide specific genomic information to understand how the disease responds to treatment at the molecular level" said Dr. Luke. "Based on the study data that Trovagene presented at medical meetings to date, we are encouraged that the DNA without urinary cell has the potential to offer a non-invasive solution for monitoring oncogenic mutations during and after treatment, and this can help physicians improve patient outcomes. "
Trovagene is engaged in numerous partnerships to demonstrate the clinical utility of its platform precision cancer surveillance for detection of the mutation status in patients with cancer, and evaluating the dynamics of the tumor and treatment response over time. to date, the company has processed over 1,000 samples of patients under its collaborations, and focuses on the development of clinical data to support the widespread adoption of its technology on the market.
Added Antonius Schuh, Ph.D., chief executive officer of Trovagene, "with this latest collaboration, we currently working with seven of the best centers of cancer treatment in the United States to demonstrate the utility of our precision cancer surveillance platform and integrate our tests in clinical practice. the Dana-Farber collaboration is initially focused on the treatment of metastatic melanoma, and we are pleased to work with Dr. Luke and colleagues to gain a better perspective on how our non-invasive tests may influence how this disease is managed. "
EmoticonEmoticon